This work is licensed under a Creative Commons Attribution 4.0 International License.
Sequence 21 from Patent US 20110159022
General Information
DRACP ID DRACP01328
Peptide Name Sequence 21 from Patent US 20110159022
Sequence CGVGFREGTCGAQ
Sequence Length 13
UniProt ID P21741
PubChem CID Not available
Origin Synthetic construct
Type Synthetic peptide
Classification
Active ACP
Activity Information
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity Not available
Target Not available
Affinity Not available
Mechanism Not available
Nature Anticancer
Structure Information
Helicity Not available
Linear/Cyclic Not available
Disulfide/Other Bond Not available
N-terminal Modification Not available
C-terminal Modification Not available
Other Modification None
Chiral L
Physicochemical Information
Formula C51H81N17O18S2
Absent amino acids DHIKLMNPSWY
Common amino acids G
Mass 149866
Pl 6.14
Basic residues 1
Acidic residues 1
Hydrophobic residues 3
Net charge 0
Boman Index -1469
Hydrophobicity 0
Aliphatic Index 30
Half Life
Mammalian: 4.4 hour
Yeast: >20 hour
E.coli: >10 hour
Extinction Coefficient cystines 125
Absorbance 280nm 10.42
Polar residues 7
Amino acid distribution
Literature Information
Literature 1
Pubmed ID Not available
Title Not available
Doi Not available
Year Not available
Patent
Patent ID US 2011/0159022 A1
Patent Title Immunogenic Peptides Derived from the Midkine Protein, as an Anticancer Vaccine.
Other Iinformation Granted Patent Family: 9s / 9ex; Family Jurisdictions: EP, US, JP, CN, CA, AU, WO, FR; Legal Status: Discontinued; Application No: 200913000302; Filed:Jun 20, 2009; Published: Jun 30, 2011; Earliest Priority: Jun 20, 2008;
Other Published ID CA2728459A1 CN102123731A EP2296697A1 WO2009153463A1
This work is licensed under a Creative Commons Attribution 4.0 International License.